Parkinsons Disease: Global Drug Forecast and Market Analysis to 2026

Parkinsons Disease: Global Drug Forecast and Market Analysis to 2026


  • Products Id :- GDHC167PIDR
  • |
  • Pages: 108
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Parkinson's Disease: Global Drug Forecast and Market Analysis to 2026

Summary

Parkinson's disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism-neurological disorders that lead to movement problems. While the exact cause of Parkinson's disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.

Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson's market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.

GlobalData estimates that drug sales for PD in 2016 were approximately USD3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to USD8.8B at a CAGR of 11.1%. This growth will be driven by the launch of thirteen late-stage pipeline products. The two highest selling drugs are expected to be Roche/Prothena's PRX-002and Acorda's CVT-301, which both address some of the unmet needs in the market.

Key Questions Answered

- What are the key PD treatments in 2016?

- When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?

- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

- Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

- Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2016 to 2026.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market

- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase III development are profiled.

- Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to-

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 6

2 Parkinson's Disease: Executive Summary 8

2.1 Parkinson's Market Forecast to Reach USD8.8B by 2026 9

2.2 New Players Expected to Establish Themselves in the Forecast Period as Late-Stage Pipeline Assets Launched 10

2.3 Disease-Modifying Agents and Late-Stage Complications the Largest Unmet Needs in the PD Market 12

2.4 Treatments for Late-Stage Complications, Including Dyskinesia and Psychosis, Provide Companies with European and Japanese Opportunity 12

2.5 Biologics and Reformulations Expected to Drive Growth Pipeline 13

2.6 What Do Physicians Think? 14

3 Introduction 17

3.1 Catalyst 17

3.2 Related Reports 18

3.3 Upcoming Related Reports 18

4 Disease Overview 19

4.1 Etiology 19

4.1.1 Overview 19

4.1.2 Aging 19

4.1.3 Environmental Factors 19

4.1.4 Genetic Factors 20

4.2 Pathophysiology 21

4.2.1 Overview 21

4.2.2 Mechanisms of Cell Death 22

5 Epidemiology 25

5.1 Disease Background 25

5.2 Risk Factors and Comorbidities 25

5.3 Global and Historical Trends 26

5.3.1 US 28

5.3.2 5EU 28

5.3.3 Japan 29

5.4 Forecast Methodology 29

5.4.1 Sources 30

5.4.2 Sources Not Used 32

5.4.3 Forecast Assumptions and Methods 32

5.5 Epidemiological Forecast for PD (2016-2026) 36

5.5.1 Diagnosed Prevalent Cases of PD 36

5.5.2 Age-Specific Diagnosed Prevalent Cases of PD 37

5.5.3 Sex-Specific Diagnosed Prevalent Cases of PD 38

5.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging 39

5.6 Discussion 40

5.6.1 Epidemiological Forecast Insight 40

5.6.2 Limitations of the Analysis 41

5.6.3 Strengths of the Analysis 42

6 Disease Management 43

6.1 Diagnosis and Treatment Overview 43

6.2 US 46

6.3 5EU 48

6.4 Japan 50

7 Competitive Assessment 53

7.1 Overview 53

8 Unmet Needs and Opportunity Assessment 55

8.1 Overview 55

8.2 Treatment of Motor Complications-Dyskinesia and OFF Episodes 57

8.3 Treatment of Non-motor Complications and Dementia 59

8.4 Neuroprotective/Disease-Modifying Agents 60

8.5 Improved Drug Formulations 62

9 Pipeline Assessment 64

9.1 Overview 64

9.2 Promising Drugs in Clinical Development 65

10 Current and Future Players 67

10.1 Overview 67

10.2 Trends in Corporate Strategy 68

10.3 AbbVie 69

10.4 Roche 69

10.5 Orion Pharma 70

10.6 Impax Pharmaceuticals 70

10.7 Acorda Therapeutics 71

10.8 Adamas Pharmaceuticals 71

10.9 UCB 72

10.10 Kyowa Hakko Kirin 72

10.11 Other Players 73

11 Market Outlook 74

11.1 Global Markets 74

11.1.1 Forecast 74

11.1.2 Drivers and Barriers-Global Issues 76

11.2 US 76

11.2.1 Forecast 76

11.2.2 Key Events 78

11.2.3 Drivers and Barriers 79

11.3 5EU 79

11.3.1 Forecast 79

11.3.2 Key Events 81

11.3.3 Drivers and Barriers 82

11.4 Japan 82

11.4.1 Forecast 82

11.4.2 Key Events 84

11.4.3 Drivers and Barriers 84

12 Appendix 85

12.1 Bibliography 85

12.2 Abbreviations 90

12.3 Methodology 92

12.3.1 Forecasting Methodology 92

12.3.2 Diagnosed Patients 93

12.3.3 Percent Drug-Treated Patients 93

12.3.4 Drugs Included in Each Therapeutic Class 93

12.3.5 Launch and Patent Expiry Dates 94

12.3.6 General Pricing Assumptions 95

12.3.7 Individual Drug Assumptions 96

12.3.8 Generic Erosion 101

12.3.9 Pricing of Pipeline Agents 101

12.4 Primary Research-KOLs [and Payers] Interviewed for This Report 102

12.4.1 KOLs 102

12.4.2 Payers 102

12.5 Primary Research-Prescriber Survey 103

12.6 About the Authors 104

12.6.1 Analyst 104

12.6.2 Therapy Area Director 104

12.6.3 Epidemiologist 105

12.6.4 Managing Epidemiologist 105

12.6.5 Global Director of Therapy Analysis and Epidemiology 106

12.6.6 Global Head and EVP of Healthcare Operations and Strategy 106

12.7 About GlobalData 107

12.8 Contact Us 107

12.9 Disclaimer 107

1.2 List of Figures

Figure 1: Global Sales Forecast by Country for Parkinson's Disease in 2016 and 2026 10

Figure 2: Analysis of the Company Portfolio Gap in Parkinson's Disease During the Forecast Period 11

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson's Disease During the Forecast Period 14

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages ?18 Years, 2016 27

Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016-2026 31

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of PD Clinical Staging, 2016-2026 32

Figure 7: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, ?18 Years, N, 2016 37

Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ?18 Years, N, 2016 38

Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ?18 Years, N, 2016 39

Figure 10: Treatment Algorithm for Parkinson's Patients 45

Figure 11: Unmet Needs and Opportunities in Parkinson's Disease 56

Figure 12: Pharmacokinetics of Levodopa 57

Figure 13: Overview of the Development Pipeline in Parkinson's Disease 64

Figure 14: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period 65

Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson's Disease During the Forecast Period 66

Figure 16: Analysis of the Company Portfolio Gap in Parkinson's Disease During the Forecast Period 68

Figure 17: Global (7MM) Sales Forecast by Country for Parkinson's Disease in 2016 and 2026 75

Figure 18: Sales Forecast by Class for Parkinson's Disease in the US in 2016 and 2026 77

Figure 19: Country Breakdown for Parkinson's Disease Sales in the 5EU in 2016 and 2026 80

Figure 20: Sales Forecast by Class for Parkinson's Disease in Japan in 2016 and 2026 83

1.1 List of Tables

Table 1: Parkinson's Disease: Key Metrics in the 7MM 8

Table 2: Risk Factors and Comorbidities for PD 26

Table 3: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages ?18 Years, N, 2016 40

Table 4: Treatment Guidelines for PD 45

Table 5: Country Profile-US 47

Table 6: Country Profile-5EU 50

Table 7: Country Profile-Japan 52

Table 8: Leading Treatments for Parkinson's Disease, 2016 54

Table 9: Comparison of Therapeutic Classes in Development for Parkinson's Disease, 2016-2026 66

Table 10: AbbVie's Disease Portfolio Assessment, 2018 69

Table 11: Roche's Disease Portfolio Assessment, 2018 70

Table 12: Orion Pharma's Disease Portfolio Assessment, 2018 70

Table 13: Impax Pharmaceuticals' Disease Portfolio Assessment, 2018 71

Table 14: Acorda Therapeutics' Disease Portfolio Assessment, 2018 71

Table 15: Adamas Pharmaceuticals' Disease Portfolio Assessment, 2018 72

Table 16: UCB's Disease Portfolio Assessment, 2018 72

Table 17: Kyowa Hakko Kirin's Disease Portfolio Assessment, 2018 73

Table 18: Parkinson's Disease Market-Global Drivers and Barriers, 2016-2026 76

Table 19: Key Events Impacting Sales for Parkinson's Disease in the US, 2016-2026 78

Table 20: Parkinson's Disease Market-Drivers and Barriers in the US, 2016-2026 79

Table 21: Key Events Impacting Sales for Parkinson's Disease in the 5EU, 2016-2026 81

Table 22: Parkinson's Disease Market-Drivers and Barriers in the 5EU, 2016-2026 82

Table 23: Key Events Impacting Sales for Parkinson's Disease in Japan, 2016-2026 84

Table 24: Parkinson's Disease Market-Global Drivers and Barriers in Japan, 2016-2026 84

Table 25: Key Projected Launch Dates for Parkinson's disease 94

Table 26: Key Historical and Projected Patent Expiry Dates for Parkinson's Disease 95

Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 103

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Teva

Roche

Prothena

Acorda Therapeutics

Voyager Therapeutics

Impax Pharmaceuticals

UCB

AbbVie

Novartis

Orion Pharmaceuticals

Intec Pharma

NeuroDerm

Adamas Therapeutics

Acadia

Sunovion

Roche

MSD

GSK

Britannia Pharmaceuticals

Novo Nordisk

Integrative Research Laboratories (IRLAB)

Lundbeck

US WorldMeds

Zambon

Eisai

Meiji Seika

Addex Therapeutics

Sanofi

Neurocrine Biosciences

Ono Pharmaceuticals

Otsuka Pharmaceutical

Takeda

Bial

Newron

Kyowa Hakko Kirin

Genzyme

select a license
Single User License
USD 10995 INR 783284
Site License
USD 21990 INR 1566568
Corporate User License
USD 32985 INR 2349851

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com